

QUALITY STANDARDS

---

# Asthma

Care in the Community  
for People 16 Years  
of Age and Older

2025 UPDATE



**Ontario  
Health**

# Scope of This Quality Standard

This quality standard addresses the diagnosis and management of asthma in adults 16 years of age and older, with a focus on primary care and community-based settings. It addresses referral to specialized asthma care for adults who meet criteria for severe asthma, but it does not address the management of severe asthma in specialized care, acute asthma exacerbations, or care provided during emergency department visits or hospitalizations.

A separate quality standard addresses [Asthma in Children and Adolescents](#).<sup>1</sup>

## What Is a Quality Standard?

Quality standards outline what high-quality care looks like for conditions or processes where there are large variations in how care is delivered, or where there are gaps between the care provided in Ontario and the care patients should receive. They:

- Help patients, families, and care partners know what to ask for in their care
- Help clinicians know what care they should be offering, based on evidence and expert consensus
- Help health care organizations measure, assess, and improve their performance in caring for patients

Quality standards and their accompanying patient guides are developed by Ontario Health, in collaboration with clinicians, patients, and care partners across Ontario.

For more information, contact [QualityStandards@OntarioHealth.ca](mailto:QualityStandards@OntarioHealth.ca).

# Quality Statements to Improve Care: Summary

These quality statements describe what high-quality care looks like for adults with asthma.

## **Quality Statement 1: Diagnosis**

Adults clinically suspected of having asthma complete spirometry to demonstrate reversible airflow obstruction and, if negative, fractional exhaled nitric oxide testing or other lung function testing to confirm the diagnosis of asthma as soon as possible.

## **Quality Statement 2: Asthma Control and Risk of Exacerbations**

Adults with asthma have a structured assessment at least annually to determine their level of asthma control, reasons for poor control, and risk of future exacerbations.

## **Quality Statement 3: Asthma Medication**

Adults with asthma receive appropriate medication and devices based on their current level of asthma control and risk of future exacerbations, including early initiation of inhaled anti-inflammatory therapy.

## **Quality Statement 4: Self-Management Education and Asthma Action Plan**

Adults with asthma and their care partners receive self-management education and a written personalized asthma action plan that is reviewed regularly with a clinician.

## **Quality Statement 5: Referral to Specialized Asthma Care**

Adults who meet criteria for severe asthma or have other appropriate indications are referred to specialized asthma care.

## **Quality Statement 6: Follow-Up After Discharge**

Adults who have had an emergency department visit or been hospitalized for an asthma exacerbation have a follow-up assessment within 2 to 7 days after discharge.

# Table of Contents

Scope of This Quality Standard .....	2
What Is a Quality Standard? .....	2
Quality Statements to Improve Care: Summary .....	3
List of Abbreviations .....	5
2025 Summary of Updates .....	6
Why This Quality Standard Is Needed .....	8
Measurement to Support Improvement .....	10
Quality Statement 1: Diagnosis.....	11
Quality Statement 2: Asthma Control and Risk of Exacerbations .....	15
Quality Statement 3: Asthma Medication .....	19
Quality Statement 4: Self-Management Education and Asthma Action Plan .....	24
Quality Statement 5: Referral to Specialized Asthma Care .....	27
Quality Statement 6: Follow-Up After Discharge .....	30
Appendix 1: About This Quality Standard .....	33
Appendix 2: Glossary.....	35
Appendix 3: Values and Guiding Principles .....	36
Acknowledgements.....	38
References .....	40
About Us.....	45

# List of Abbreviations

Abbreviation	Definition
<b>ACQ</b>	Asthma Control Questionnaire
<b>ACT</b>	Asthma Control Test
<b>ATS</b>	American Thoracic Society
<b>BTS</b>	British Thoracic Society
<b>bud/form</b>	budesonide/formoterol
<b>CAE</b>	certified asthma educator
<b>CRE</b>	certified respiratory educator
<b>CTS</b>	Canadian Thoracic Society
<b>DPI</b>	dry powder inhaler
<b>ERS</b>	European Respiratory Society
<b>FeNO</b>	fractional exhaled nitric oxide
<b>FEV<sub>1</sub></b>	forced expiratory volume in 1 second
<b>FVC</b>	forced vital capacity
<b>ICS</b>	inhaled corticosteroid
<b>LABA</b>	long-acting $\beta$ 2-agonist
<b>LLN</b>	lower limit of normal
<b>LTRA</b>	leukotriene receptor antagonist
<b>MDI</b>	metered-dose inhaler
<b>NICE</b>	National Institute for Health and Care Excellence
<b>PEF</b>	peak expiratory flow
<b>ppb</b>	parts per billion
<b>SABA</b>	short-acting $\beta$ 2-agonist
<b>SIGN</b>	Scottish Intercollegiate Guidelines Network

# 2025 Summary of Updates

In 2024, we completed a review of the evidence to capture new or updated clinical practice guidelines and health technology assessments published since the original release of this quality standard in 2020. This update aligns the quality standard with the most recent clinical evidence and with current practice in Ontario.

Below is a summary of changes to the overall quality standard:

- Updated links, secondary references, and data sources where applicable
- Revised the accompanying resources (i.e., patient guide, placemat, case for improvement slide deck, technical specifications) to reflect changes to the quality standard
- Updated the data in the Why This Quality Standard Is Needed section and in the case for improvement slide deck, where applicable
- Revised the Guiding Principles section and added a guiding principle on integrated care
- Updated terminology throughout where applicable, including:
  - *Caregiver* changed to *care partner*
  - *Family doctor or nurse practitioner* changed to *primary care clinician*
  - *Health care professional* changed to *clinician*

Below is a summary of changes to specific quality statements:

- Quality statement 1:
  - Updated the quality statement to include FeNO testing as well as other lung function testing, and added an associated definition
  - Updated the definition of *spirometry* to use a race-neutral approach for interpreting spirometry based on the recent ATS consensus statement,<sup>2</sup> and to include the recently updated ERS and ATS definition of bronchodilator reversibility supportive of a diagnosis of asthma<sup>3</sup>
- Quality statement 2:
  - Updated the quality statement to include an assessment for risk of future exacerbations and an associated definition
  - Updated the definition of *symptom control* to decrease the target for the frequency of daytime symptoms and for the need for reliever medication from < 4 days per week and < 4 doses per week to ≤ 2 days per week and ≤ 2 doses per week, respectively
  - Modified the definition of *lung function* to highlight that FeNO testing is not recommended for monitoring asthma control and risk of future exacerbations

- Updated the definition of *at least annually* to align criterion for SABA overuse with updated CTS 2021 guidelines<sup>4,5</sup>
- Quality statement 3:
  - Updated the quality statement to add “risk of future exacerbations” and a brief definition referring to the fulsome definition in quality statement 2
  - Updated the definition of *appropriate medication and devices* to add considerations for the use of low carbon footprint inhalers in alignment with the Choosing Wisely Canada recommendation and CTS position statement,<sup>6,7</sup> and to emphasize shared decision-making
  - Updated the definition of *appropriate medication and devices* and the “For Clinicians” audience statement to align the stepwise approach for medications with the updated CTS 2021 guidelines and the BTS, NICE, and SIGN 2024 guideline,<sup>4,5,8</sup> and to emphasize shared decision-making
- Quality statement 4:
  - Updated the definition of *self-management education* to include considerations for virtual care or computerized decision support systems, based on the BTS, NICE, and SIGN 2024 guideline<sup>8</sup>
- Quality statement 5:
  - Updated the definition of *appropriate indications* for referral to specialized asthma care to align the criterion on the number of emergency department visits with the CTS 2021 guideline,<sup>4</sup> remove uncontrolled asthma, and separate near-fatal exacerbations and uncontrolled asthma in pregnancy
- Quality statement 6:
  - Added “advisory committee consensus” as a source due to the lack of recommendations within updated guidelines
  - Updated the definition of *follow-up assessment* to include referral to an asthma education program, as well as to specialized asthma care for adults who were hospitalized and/or required treatment in intensive care

# Why This Quality Standard Is Needed

Asthma is a chronic inflammatory disorder of the airways in the lungs. In people with asthma, the airways become inflamed and obstructed, usually because they are hyperresponsive to internal and external factors, commonly called triggers (e.g., allergens, irritants).<sup>9,10</sup> People with asthma typically experience difficulty breathing, shortness of breath, chest tightness, wheezing (a whistling sound produced in the airways during breathing), sputum (mucus) production, and/or cough. These symptoms can be episodic or persistent. As with many chronic conditions, the cause of asthma is not known with certainty, but it is thought to develop from interactions between genetic and environmental factors such as a family history of asthma and exposure to smoke, air pollution, or occupational vapours or particles.<sup>11</sup> When asthma appears in adulthood, an estimated 10% to 25% of cases are work related.<sup>12,13</sup>

Asthma is one of the most common chronic conditions in Canada. In Ontario, it is estimated that nearly 2.5 million people were living with asthma in 2022/23.<sup>14</sup> In recent years, the incidence of asthma in Ontario (the number of people newly diagnosed each year) has been decreasing for all age groups combined; it dropped from nearly 8 new cases per 1,000 people in 2000/01 to 3 per 1,000 in 2022/23.<sup>15</sup> At the same time, because people are generally living longer, the prevalence of asthma in Ontario (the number of people living with the disease) continued to increase for all age groups combined; it rose from around 114 per 1,000 people in 2000/01 to 156 per 1,000 in 2022/23.<sup>14</sup> Both incidence and prevalence vary substantially across the province; in 2022/23, the East region had the highest prevalence rate of asthma, whereas the Toronto region had the lowest prevalence rate.<sup>14,15</sup>

People diagnosed with asthma are more likely to have other chronic diseases and conditions such as diabetes, hypertension, and mood or anxiety disorders.<sup>16,17</sup> As a result, they often experience an overall poorer quality of life compared with the general population. The presence of comorbidities can also worsen asthma symptoms or the asthma itself, thus impeding appropriate asthma management.<sup>18</sup>

Although asthma has no cure, most people can control their asthma by using appropriate controller medications, such as ICS, and reducing their exposure to triggers. The primary goal of asthma care is to help people achieve and maintain asthma control, which reduces their risk of having an exacerbation (a flare-up or asthma attack) and improves their overall health and quality of life.<sup>11</sup> Current guidelines stress that, with appropriate management in primary care, most people with asthma should be able to live symptom free. Exacerbations requiring oral corticosteroids, an emergency department visit, or hospitalization should usually be considered a failure of asthma management. Every asthma death should be considered preventable.<sup>4,5,19-21</sup>

However, it is estimated that 50% of people with asthma in Canada have uncontrolled disease, resulting in unnecessary reductions in quality of life and avoidable illness and deaths.<sup>22,23</sup> In Ontario, about 90 people die from asthma each year (1,704 deaths from 2000 to 2018<sup>24</sup>). The age- and sex-adjusted all-cause mortality rate for people living with asthma remains higher than for the population overall (in 2008, there were 852 deaths per 100,000 people with asthma versus 640 per 100,000 in the general population<sup>25</sup>).



Uncontrolled asthma also contributes to high health care use and costs. Overall use of health services for people with asthma has been shown to be much higher for people with uncontrolled asthma<sup>26</sup> and particularly high in the year prior to asthma-related deaths.<sup>8,10</sup> Among people aged 15 years and older in Ontario in 2022/23, there were over 16,000 asthma-specific emergency department visits<sup>27</sup> and over 8,000 asthma-specific hospitalizations.<sup>28</sup>

Asthma is also associated with substantial indirect costs to society, such as absenteeism from school and work.<sup>11</sup> The economic burden of asthma in Ontario (direct health care costs plus indirect social costs) was estimated at \$1.8 billion in 2011.<sup>29</sup> The direct costs of asthma to the Canadian economy are projected to climb to \$4.2 billion annually by 2030.<sup>30</sup>

These data highlight opportunities for improving the management of asthma in primary care and community-based care settings. This standard focuses on helping clinicians diagnose asthma appropriately, recognize and address uncontrolled asthma, escalate and taper medication optimally, empower people with asthma to self-manage using an asthma action plan, and support safe, effective transitions in care. Improving the quality of asthma care can help people better control their disease, preventing acute exacerbations, emergency department visits, hospital admissions, and deaths.

# Measurement to Support Improvement

The Asthma Quality Standard Advisory Committee identified 6 overarching indicators to monitor the progress being made toward improving care for adults with asthma in Ontario.

## Indicators That Can Be Measured Using Provincial Data

- Percentage of adults with incident asthma whose diagnosis is confirmed with lung function testing
- Percentage of adults with asthma who visited the emergency department for an asthma-specific reason in the previous 12 months

## Indicators That Can Be Measured Using Only Local Data

- Percentage of adults with asthma who had a structured assessment in the previous 6 months
- Percentage of adults with asthma with 1 or more appropriate indications who are prescribed inhaled anti-inflammatory therapy
- Average number of asthma symptom-free days in the previous 4 weeks among adults with asthma
- Average number of days missed from school or work due to asthma in the previous 4 weeks

# Quality Statement 1: Diagnosis

Adults clinically suspected of having asthma complete spirometry to demonstrate reversible airflow obstruction and, if negative, fractional exhaled nitric oxide testing or other lung function testing to confirm the diagnosis of asthma as soon as possible.

Sources: British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network, 2024<sup>8</sup> | Canadian Thoracic Society, 2021a<sup>4</sup> | European Respiratory Society, 2022<sup>31</sup> | National Heart, Lung, and Blood Institute and National Institutes of Health, 2020<sup>32</sup> | Ontario Health, 2024<sup>33</sup> | Registered Nurses' Association of Ontario, 2017<sup>11</sup>

## Definitions

**Clinically suspected of having asthma:** Asthma is clinically suspected in the presence of signs and/or symptoms of variable airflow obstruction and in the absence of an alternative diagnosis (e.g., other respiratory conditions, cardiovascular disease). Signs or symptoms of airflow obstruction include shortness of breath, chest tightness, wheezing, and/or cough. The presence of respiratory signs and symptoms should be assessed through a structured clinical history and physical examination, then documented in the medical record. Because an estimated 10% to 25% of adult-onset asthma cases are work related, a detailed occupational exposure history should also be taken to identify any relationship between symptoms and work activities and whether there are allergens or irritants in the workplace that may be causing or contributing to respiratory symptoms.

Respiratory symptoms characteristic of asthma often<sup>10</sup>:

- Include more than 1 symptom (e.g., shortness of breath, chest tightness, wheezing, cough)
- Vary in intensity or over time (e.g., worse at night and/or in the early morning)
- Are caused by allergens (e.g., dust mites, pet dander, cockroaches, pollen, mould), irritants (e.g., infections, smoke, fumes, chemicals, extreme air temperatures, exercise, thunderstorms), workplace exposures (e.g., allergens, irritants), or other triggers (e.g., rhinitis, sinusitis, gastroesophageal reflux, food and drug reactions, laughter, hormonal changes during menstruation and pregnancy)

**Spirometry:** This is the preferred lung function test to diagnose asthma by assessing for airflow obstruction and its reversibility.<sup>4</sup> The test measures airflow as the ratio of forced expiratory volume in 1 second (FEV<sub>1</sub>), which is the volume of air exhaled during the first second of the forced vital capacity (FVC) measurement, and FVC, which is the volume of air forcibly exhaled from the point of maximal inspiration. Results are presented as a percentage of the predicted value or as an absolute value, for each volume, to be compared with the lower limit of normal (LLN). The FEV<sub>1</sub>/FVC ratio is calculated

from absolute values. Reference values to interpret the test are generally based on age, sex, and height.

Traditionally, race has also been factored into spirometry reference values on the theoretical basis that biological differences between races influence expected lung function. However, race is a dynamic social construct that encompasses values, structures, and practices, rather than a well-defined biological construct. Furthermore, recent data show that social determinants such as socioeconomic status and education are more strongly correlated with lung function than race.<sup>34</sup> Accordingly, the use of race to set reference values inadvertently normalizes historical socioeconomic and other disadvantages suffered by people from racialized groups, which can perpetuate and amplify race-based inequities and structural racism. To address this issue, the ATS has developed a consensus statement, endorsed by the ERS, that concludes that race and ethnicity should no longer be considered factors in interpreting the results of spirometry. Rather, a race- and ethnicity-neutral approach to interpreting spirometry, using average reference equations (e.g., the Global Lung Function Initiative average equation), promotes health equity and minimizes negative impacts on people from racialized groups.<sup>2,35</sup> The CTS, the ATS, and other respiratory care societies have collaboratively conducted a comprehensive evidence review, explored the clinical implications of using race and ethnicity in the interpretation of pulmonary function testing, and identified a number of research gaps in this area, suggesting that ongoing research is needed to mature our understanding of the implications of this change in reference values for people from racialized groups.<sup>36</sup>

Spirometry should be performed before and after the administration of an inhaled bronchodilator. A pre-bronchodilator FEV<sub>1</sub>/FVC result less than the LLN (approximately < 0.70–0.80) demonstrates airflow obstruction. A post-bronchodilator increase in FEV<sub>1</sub> of at least 12% and 200 mL from baseline, or of 10% of the predicted normal FEV<sub>1</sub> or FVC, supports the diagnosis of asthma.<sup>3,37</sup> The new definition of a 10% change in the predicted normal FEV<sub>1</sub> or FVC is the preferred threshold for defining bronchodilator response; however, adopting this change will take time due to required updates to software, equipment, and interpretation algorithms. A CTS position statement on the adoption of this new definition with considerations for the Canadian population is currently under development. A negative spirometry test does not rule out asthma, especially when asthma is controlled, because of the low sensitivity of the test. In such cases, additional lung function testing is required to confirm the diagnosis of asthma. In situations where people cannot perform spirometry, a referral to specialized asthma care may be considered (see quality statement 5).

**Fractional exhaled nitric oxide (FeNO):** FeNO is present in larger amounts when the airways are inflamed. FeNO testing should be considered as an adjunct test, with levels of  $\geq 50$  ppb supporting a diagnosis of asthma. As current evidence evolves and FeNO testing becomes more readily available, it may be a reasonable first-line alternative test to spirometry. A FeNO of < 50 ppb does not rule out asthma. FeNO levels may also be affected (lowered) by smoking or following systemic or ICS treatment.<sup>31</sup>

**Other lung function testing:** In Ontario, the following tests are recommended to confirm a diagnosis of asthma<sup>4</sup>:

- **Challenge tests** are an alternative method to diagnose asthma when spirometry is negative. They assess for airway hypersensitivity and hyperresponsiveness. Challenge tests are also known as

bronchial provocation tests and can be direct, such as the methacholine challenge test, or indirect, such as the exercise challenge test. Methacholine challenge tests should not be performed within several weeks of an active infection. In the presence of ongoing clinical symptoms, a negative methacholine challenge test may be most helpful in ruling out asthma.<sup>38</sup> Bronchodilators should be withheld prior to testing in accordance with their duration of action. If safe to do so, ICS treatment should be withheld for 4 to 8 weeks prior to testing to remove the anti-inflammatory effect on the airways<sup>38</sup>

- **PEF measurement** assesses the presence of airflow variation over the span of 2 weeks. A variation in PEF of greater than 20% supports a diagnosis of asthma

**As soon as possible:** Spirometry, followed by other lung function testing if spirometry is negative or not possible, should be performed to confirm the diagnosis of asthma as soon as possible and within at most 3 months of a person seeking care for their respiratory symptoms. A trial of medication may be considered if testing cannot be reliably or expediently performed, but confirmatory testing should still be completed, regardless of the outcome of the therapeutic trial.<sup>4</sup> Every attempt should be made to ensure the asthma diagnosis can be confirmed with lung function testing, especially if any changes in the person's condition suggest they may be able to undergo testing. This includes the re-evaluation of an adult diagnosed with asthma in childhood without objective measures.

## Rationale

In Ontario, spirometry and other lung function testing to diagnose asthma is increasing but not yet routine. According to available administrative health data, about half of people 7 years of age and older receive lung function testing within 1 year prior to or 2.5 years after their incident date to confirm their diagnosis.<sup>39</sup>

Often, asthma is diagnosed based on symptoms and history, without spirometry or other lung function testing.<sup>23,40</sup> There is a risk of misdiagnosis when reversible airflow obstruction is not confirmed with lung function testing, since other conditions can cause asthma-like symptoms.<sup>23</sup> In addition to inappropriate treatment, a false misdiagnosis of asthma can lead to delays in making the correct diagnosis.<sup>40</sup>

Without lung function testing, an asthma diagnosis may also be missed, leading to inappropriate treatment with nonasthma medications (e.g., antibiotics for chronic cough). Failure to diagnose asthma and begin appropriate medication also increases the risk of the person having a severe asthma exacerbation.<sup>23</sup>

## What This Quality Statement Means

### For Adults Suspected of Having Asthma

If your symptoms include shortness of breath, a feeling of tightness in your chest, wheezing, or cough, your primary care clinician should make sure you have a breathing test before they diagnose you with

asthma. They may offer you medication while you wait to have this test done. Once your test results are available, your primary care clinician will review the results with you.

### For Clinicians

Administer or order spirometry for adults clinically suspected of having asthma to confirm a diagnosis of asthma. Given the low sensitivity of spirometry with bronchodilator response testing for the diagnosis of asthma, in cases of suspected asthma in which spirometry with bronchodilator response testing is negative, FeNO testing or additional lung function testing such as methacholine challenge testing is required to assess possible asthma.

Testing should occur as soon as possible and ideally be completed within at most 3 months of a person seeking care for their respiratory symptoms. Once results are available, review the results with patients. Longer wait times should not deter clinicians from ordering and seeking appropriate lung function testing before confirming a diagnosis of asthma. Document signs and symptoms of variable airflow obstruction obtained from clinical history, physical examinations, and objective measures as the basis for diagnosing asthma.<sup>8</sup>

### For Organizations and Health Services Planners

Ensure lung function testing is locally available and accessible. Ensure clinicians in primary care and community-based settings are aware of the local availability of lung function testing<sup>8</sup> and can order appropriate lung function testing for people clinically suspected of having asthma, including spirometry, FeNO testing, and challenge tests, without first referring to specialized asthma care. Ensure local availability of FeNO testing for use in conjunction with spirometry.<sup>33</sup> Ensure spirometry is performed within a quality assurance program by trained clinicians.<sup>8,11</sup>

## Quality Indicators: How to Measure Improvement for This Statement

- Percentage of adults clinically suspected of having asthma who complete lung function testing within 3 months of seeking care for their respiratory symptoms
- Local availability of lung function testing

Measurement details for these indicators, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).

# Quality Statement 2: Asthma Control and Risk of Exacerbations

Adults with asthma have a structured assessment at least annually to determine their level of asthma control, reasons for poor control, and risk of future exacerbations.

Sources: British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network, 2024<sup>8</sup> | Canadian Thoracic Society, 2021a<sup>4</sup>, 2021b<sup>5</sup> | National Heart, Lung, and Blood Institute and National Institutes of Health, 2020<sup>32</sup> | Ontario Health, 2024<sup>33</sup> | Registered Nurses' Association of Ontario, 2017<sup>11</sup>

## Definitions

**Structured assessment to determine level of asthma control:** Asthma control parameters for adults include measures of symptoms, lung function, and airway inflammation.

### *Symptom control*

Symptom control over the previous 4 weeks should be assessed at least annually, using validated symptom-control questionnaires and tools (e.g., ACT, ACQ) to evaluate the following criteria<sup>4,5</sup>:

- Daytime symptoms (target  $\leq 2$  days per week)
- Nighttime symptoms (target  $< 1$  night per week, and mild symptoms)
- Frequency of need for rescue or reliever medication (target  $\leq 2$  doses per week)
- Physical activity (target normal)
- Absence from work or school due to asthma (target none)

Frequency and severity of exacerbations (target infrequent and mild) should be assessed since the last health care encounter in which they were assessed.<sup>4</sup>

### *Lung function*

Lung function should be assessed with spirometry and other lung function testing as needed (1) at the start of treatment; (2) after 3 to 6 months of treatment to identify and document response to treatment and the person's personal best FEV<sub>1</sub>; and (3) annually for ongoing assessment of asthma control and risk of exacerbation.<sup>41</sup> The following measures of lung function should be assessed:

- FEV<sub>1</sub> (target  $\geq 90\%$  of personal best)
- If spirometry is unavailable, PEF can be used (target diurnal variation  $< 10\%–15\%$ )<sup>4</sup>



Based on current evidence and technology, FeNO testing is not recommended to monitor asthma control and risk of future exacerbations.<sup>4,8,33</sup>

### **Airway inflammation**

Airway inflammation should also be assessed for adults with uncontrolled moderate to severe asthma receiving care in specialist centres:

- Sputum eosinophils (target < 2%–3%)

**At least annually:** Symptom control and any reasons for poor control should be assessed at least annually using a structured assessment, and in some cases more frequently: (1) at every asthma-related health care encounter; (2) after a severe exacerbation of symptoms; (3) when there is a change in treatment; (4) when a pattern of SABA overuse is detected within a year (defined as > 2 SABA inhalers used in 1 year)<sup>4</sup>; and (5) when there are complex health needs. In some cases, a phone or virtual health care encounter may be sufficient to assess asthma symptom control. Lung function should be assessed at least annually as described above.

**Reasons for poor control:** Clinicians should explore the following reasons for poor control, as these factors can increase the risk of more severe asthma exacerbations and contribute to poor quality of life:

- Inadequate adherence to controller medication (e.g., ICS underuse due to side effects, attitudes and goals for asthma treatment, affordability)
- Incorrect inhaler technique
- Exposure to allergic triggers and irritants, including workplace exposures (e.g., colds, allergens, smoke, cigarette or wildfire smoke, electronic cigarette vapours, inhaled cannabis, chemicals, perfumes or scents)
- Symptomatic comorbidities (e.g., rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obesity, obstructive sleep apnea, depression, anxiety)<sup>4,10</sup>
- Impacts of social determinants of health and the challenges with accessing supports to address these impacts (e.g., education, employment, ethnicity and culture, family and social support, housing, geographic location, income, transportation, and access to care)

**Risk of future exacerbations:** People with any of the following risk factors are at significantly higher risk for an exacerbation of asthma<sup>4,5,10</sup>:

- History of a previous severe asthma exacerbation requiring systemic steroids, an emergency department visit, and/or hospitalization
- Uncontrolled asthma
- SABA overuse (use of > 2 inhalers in 1 year)
- Current smoking or vaping



# Rationale

Asthma control and risk of future exacerbations should be assessed at least annually in primary care.<sup>4,5,8</sup> Assessing control is an important gap in care for adults with asthma. A longitudinal audit of primary care practice in Ontario in 2012 and 2013 found that only 15% of patients had had an assessment to determine their level of asthma control at least once during the study period.<sup>42</sup> Clinicians assessed asthma symptom control with at least 1 question from guideline recommendations in only 6% of visits (261 of 4,122 visits). Among these visits, they asked 1.6 of a recommended 5 questions, on average. They asked about daytime symptoms in 61% of visits with any asthma control assessment; frequency of need for reliever medication (45%); nighttime symptoms (27%); physical activity limitations (23%); and school or work absenteeism (4%). All 5 asthma control criteria were assessed in only 1.5% (n = 4) of these visits.<sup>42</sup>

In addition, there is a widening gap between current practice and the recommended annual assessment of lung function (see definition in this statement). The percentage of people who received asthma-related care and had lung function testing within that same year decreased by more than half in Ontario, from 10.3% in 2000/01 to 4.5% in 2022/23.<sup>39</sup> (Data for fiscal year 2022/23 may be incomplete due to the 2-year algorithm to identify asthma, which means that numbers are subject to change. In addition, due to the observed underutilization of health care services during the COVID-19 pandemic beginning in 2020/21, data captured during this time period may be underestimated.)

The lack of ongoing assessment of asthma control is concerning because an estimated 50% of people with the disease have uncontrolled asthma.<sup>22,23</sup> Uncontrolled asthma is most commonly associated with nonadherence to medication, incorrect inhaler technique, lack of objective diagnosis (see quality statement 1), and poor management of comorbidities.<sup>4</sup> These and other reasons for poor control can be identified and addressed to help people achieve and maintain asthma control.<sup>4</sup>

## What This Quality Statement Means

### For Adults With Asthma

A clinician should see you at least annually to check on your asthma. If you have a severe flare-up or you have a change in your medication, your clinician may need to see you more often. At these appointments, they should explain how you can expect to feel when your asthma is controlled, and they should ask you about:

- Your asthma symptoms and what makes them worse
- Your use of medications
- Anything else that might be affecting how you feel

You can help by keeping track of these details between appointments.

### For Clinicians

Inform patients they can expect to live symptom free when asthma is controlled. Assess asthma symptom control according to recommended criteria regularly, and at least annually. The structured assessment should determine the person's level of asthma symptom control, any reasons for poor control, and risk of future exacerbations so they can be addressed before modifying medication (see quality statement 3). Whenever possible, ensure spirometry and other lung function testing as needed are done as described above.

### For Organizations and Health Services Planners

Ensure people with asthma are informed that they can expect to live symptom free when their asthma is controlled. Ensure training, systems, processes, and resources are in place in primary care and community-based settings for clinicians to – at least annually and according to recommended criteria – assess asthma symptom control, reasons for poor control, and risk of future exacerbations. Ensure the local availability and accessibility of lung function testing to monitor asthma control.

## Quality Indicators: How to Measure Improvement for This Statement

- Percentage of adults with asthma who had a structured assessment in the previous 6 months
- Percentage of adults with asthma who completed a lung function test in the previous 12 months

Measurement details for these indicators, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).

# Quality Statement 3: Asthma Medication

Adults with asthma receive appropriate medication and devices based on their current level of asthma control and risk of future exacerbations, including early initiation of inhaled anti-inflammatory therapy.

Sources: British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network, 2024<sup>8</sup> | Canadian Thoracic Society, 2021a<sup>4</sup>, 2021b<sup>5</sup> | Registered Nurses' Association of Ontario, 2017<sup>11</sup>

## Definitions

**Appropriate medication and devices:** All adults with a confirmed diagnosis of asthma should be offered medication based on their current level of asthma control (see quality statement 2) and the most appropriate inhaler devices and spacer device to meet their needs. (A spacer device is a long tube with a valve that can be attached to MDIs to make it easier to inhale the medication.) Lower carbon footprint inhalers (e.g., DPI) containing medications with comparable efficacy should be considered where available.<sup>6,7</sup> A shared decision-making approach that considers the safety, cost, and environmental benefits of alternatives to greenhouse gas-intensive MDIs, as well as the patient's inhalation technique and the inspiratory flow rate or pressure required for adequate medication delivery, should be adopted.

Those with 1 or more criteria of uncontrolled asthma should have their medication escalated to help them gain control, but only after addressing other reasons for poor control (e.g., by counselling on smoking cessation, elimination of tobacco and cannabis smoke exposure, and allergen avoidance or immunotherapy [if indicated]). Reasons for poor control include, but are not limited to, symptoms of comorbid conditions, trigger exposures (e.g., colds, allergens, cigarette smoke, electronic cigarette vapours, workplace irritants), incorrect inhaler technique, and overreliance on rescue or reliever medication with inadequate use of controller medication (see quality statement 2).

Once the person with asthma has achieved control with at least 3 to 6 months of daily anti-inflammatory medication, medication should be reduced to the lowest effective dose required to maintain asthma control, prevent future exacerbations, and minimize side effects unless previous recent attempts have failed.

Medication should be offered, escalated, and de-escalated as follows:

- **Step 1:** Adults who experience symptoms less than 2 times per week, have otherwise well-controlled asthma, and have no risk factors for exacerbations may use as-needed inhaled short-acting reliever medication in the form of a SABA<sup>4,5</sup>

- **Step 2:** Adults who experience symptoms 2 or more times per week or meet other criteria for uncontrolled asthma should be offered a daily inhaled anti-inflammatory medication in the form of a low-dose ICS with as-needed SABA reliever medication.<sup>4,5,8,43</sup> As-needed bud/form may be an alternative option to low-dose ICS with as-needed SABA for adults who experience difficulties adhering to daily low-dose ICS despite self-management education and support.<sup>5</sup> Daily use of an oral anti-inflammatory medication in the form of an LTRA with as-needed SABA reliever medication is a second-line step 2 therapy<sup>4,5</sup>
  - For adults who have well-controlled asthma but have a significantly higher risk of exacerbation, as-needed bud/form is considered an equivalent alternative to a low-dose ICS with as-needed SABA reliever medication for first-line therapy at this step<sup>5</sup>
- **Step 3:** Adults who have uncontrolled asthma while using a daily inhaled anti-inflammatory medication in the form of a low-dose ICS should be offered a daily combined inhaled anti-inflammatory and long-acting reliever medication at a low dose (i.e., an ICS/ LABA) with as-needed SABA reliever medication. Those who have uncontrolled asthma while using as-needed bud/form may similarly be switched to daily use of this medication. Second-line step 3 therapies include continuing to take daily low-dose ICS and adding a daily LTRA, or escalating to a medium-dose ICS<sup>4,5</sup>
- **Step 4:** Adults who have uncontrolled asthma while using a daily combined inhaled anti-inflammatory and long-acting reliever medication in the form of low-dose ICS/LABA should be offered a daily medium-dose ICS/LABA with as-needed SABA, or can be switched to bud/form maintenance and reliever therapy at the same maintenance ICS dose. Second-line step 4 therapies include continuing to take a daily low-dose ICS/LABA and adding a daily LTRA or continuing to take a daily low-dose ICS/LABA and adding daily tiotropium<sup>4,5</sup>
- **Step 5:** Adults who have uncontrolled asthma while using daily step 4 medications should be offered daily high-dose ICS/LABA (with as-needed SABA or bud/form used as a reliever medication) and should be referred to specialized asthma care, as a specialist may prescribe life-altering medications known as biologics (see quality statement 5)

Medication de-escalation can be attempted once the person with asthma has achieved control for at least 3 to 6 months.

Adults with clinically suspected asthma not yet confirmed with lung function testing may be prescribed a trial of therapy if testing cannot be reliably or expediently performed, but confirmatory lung function testing should still be completed as soon as possible, regardless of the outcome of the therapeutic trial (see quality statement 1).<sup>4</sup>

**Asthma control:** Parameters include measures of symptoms, lung function, and airway inflammation, as described in quality statement 2.

**Risk of future exacerbations:** This includes patient-specific risk factors as described in quality statement 2.

## Rationale

Asthma management aims to control the disease and, by doing so, prevent or minimize the risk of short- and long-term complications and death.<sup>4</sup> Because uncontrolled asthma is commonly associated with overreliance on rescue or reliever medication and inadequate use of controller medication, care delivery that follows guideline recommendations for medication escalation can help to improve asthma control.

However, appropriate medication as a component of asthma management often depends on other key components of high-quality asthma care, such as regular assessment of asthma control, reasons for poor control, and risk of future exacerbations (see quality statement 2) and the use of asthma action plans along with asthma education (see quality statement 4).<sup>10</sup> Therefore, discussions about appropriate medication and devices between the person with asthma and their clinician should promote patient empowerment, shared decision-making, and self-management. This can include discussions of the patient's preferences, such as goals, beliefs, and concerns about asthma and medications; their preferences for strategies to achieve control and to reduce the risk of asthma exacerbations (while considering individual characteristics or phenotype); and practical issues, such as inhaler technique, controller medication adherence, and the affordability of medications.<sup>10</sup>

The need for increased knowledge among prescribers about optimal escalation and tapering of asthma medication continues to be an important part of appropriate prescribing. Despite recommendations for the early initiation of inhaled anti-inflammatory therapy and for escalating or tapering the controller medication based on patients' asthma control level, a longitudinal practice audit in Ontario found large gaps in care.<sup>42</sup> Many people with uncontrolled asthma (55%) were not prescribed any inhaled anti-inflammatory medication, and, among those who were prescribed anti-inflammatory medication, only half had it escalated from ICS alone to ICS with a LABA or ICS with an LTRA.<sup>42</sup>

## What This Quality Statement Means

### For Adults With Asthma

Most adults with asthma can live symptom free by regularly using their controller puffer and by avoiding triggers as much as possible. Your primary care clinician should talk with you about your goals, beliefs, and concerns about asthma and medications so you can decide together what asthma medication and devices would work best for you. They should:

- Explain when to use your puffers and show you how to use them
- Ask you to show them how you use your puffers to make sure you are confident using them

There are many different types of asthma medication. If you continue to have asthma symptoms while using your current medications, talk with your primary care clinician about trying a different

dose or a different asthma medication. When you fill prescriptions, your pharmacist will teach you to use the medication and answer any questions you have. It is important to take your controller medication every day if your primary care clinician has prescribed it this way.

## For Clinicians

Prescribe medications based on the person's level of asthma control and risk of future exacerbations. Escalate medication according to the steps described in this statement's definitions, only after addressing other reasons for poor control (see quality statement 2). Initiate a low-dose ICS as a regular controller medication for adults with a confirmed diagnosis of asthma who experience asthma symptoms 2 or more times per week or meet other criteria for uncontrolled asthma. Adults who experience difficulties adhering to daily low-dose ICS despite self-management education and support may be prescribed as-needed bud/form as an alternative. For adults who have well-controlled asthma but have a significantly higher risk of future exacerbations, as-needed bud/form is considered an equivalent alternative to a low-dose ICS with as-needed SABA reliever medication for first-line therapy. Once the person with asthma has achieved control with at least 3 to 6 months of daily anti-inflammatory medication, medication should be reduced to the lowest effective dose required to maintain asthma control, prevent future exacerbations, and minimize side effects unless previous recent attempts have failed.

For people without a confirmed asthma diagnosis, prescribe a trial of medication only if lung function testing cannot be reliably or expediently performed (see quality statement 1). Confirmatory testing should still be completed, regardless of the outcome of the therapeutic trial.<sup>4</sup>

When prescribing or dispensing asthma medication, provide clear instructions about when and how to properly use the medication and its delivery system. Teach proper inhaler technique and use of a spacer device, if needed, and ask people to demonstrate how they use their inhaler to ensure proper technique. (This patient education method is called "teach back."). A validated point-of-care conversation aid, such as the [Asthma Decision Aid](#), can be used with patients 12 years of age and older with mild asthma to support shared decision-making when selecting between daily low-dose ICS and as needed bud/form.

## For Organizations and Health Services Planners

Ensure training, systems, processes, and resources are in place in primary care and community-based settings for clinicians to prescribe appropriate medication and devices based on the level of asthma control. Ensure adults with asthma can access and afford the medication and devices most appropriate for them.

# Quality Indicators: How to Measure Improvement for This Statement

- Percentage of adults with asthma with 1 or more appropriate indications who are prescribed inhaled anti-inflammatory therapy

- Percentage of adults with uncontrolled asthma who have had all their reasons for poor control addressed
- Percentage of adults with uncontrolled asthma who have their medication escalated after other reasons for poor control have been addressed

Measurement details for these indicators, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).



# Quality Statement 4: Self-Management Education and Asthma Action Plan

Adults with asthma and their care partners receive self-management education and a written personalized asthma action plan that is reviewed regularly with a clinician.

Sources: British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network, 2024<sup>8</sup> | Canadian Thoracic Society, 2021a<sup>4</sup> | Registered Nurses' Association of Ontario, 2017<sup>11</sup>

## Definitions

**Self-management education:** This is tailored to the person's learning needs and provided by a trained clinician. It should include information and support related to the following issues<sup>11</sup>:

- Medication adherence (e.g., side effects, attitudes and goals for asthma treatment, affordability)
- Medication delivery device and inhaler technique
- Identification and avoidance or reduction of exposure to allergic and irritant triggers (e.g., pet dander, mould, colds, smoke, air pollution, extreme air temperatures, chemicals, perfumes or scents)
- Smoking prevention and cessation for the person with asthma and other people in their household (e.g., vaping, tobacco, cannabis)
- Impact of comorbidities on asthma symptoms and importance of management of comorbidities (e.g., rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obesity, obstructive sleep apnea, depression, anxiety)<sup>4,10</sup>
- Use of peak flow meters when indicated

To ensure people are empowered to self-manage their asthma, clinicians who provide self-management education and supports should consider the social determinants of health and the person's circumstances (e.g., education, employment, ethnicity and culture, family and social support, housing, geographic location, income, transportation, and access to care). Self-management education may be provided in-person or virtually, and can be further supported using computerized decision support systems adapted for patient use such as the [Electronic Asthma Management System](#) (eAMS).<sup>8</sup>

**Asthma action plan:** A written personalized asthma action plan (sometimes referred to as an AAP) is provided alongside self-management education. It typically uses 3 "zones" (similar to traffic light colours: green, yellow, and red) to describe the level of asthma control. It is a collaboratively written



set of instructions that is explained and provided to the person with asthma and/or their care partner(s) to assist them with the following:

- How to assess their asthma control (self-monitoring)
- How to maintain good control and prevent asthma exacerbations by regularly using controller medication
- How to identify signs, symptoms, and/or peak flow rate indicating uncontrolled asthma
- What to do during periods of uncontrolled asthma, such as adding medications or increasing the dose of medication; how much medication to take and for how long; and when and how to seek help (e.g., when to call their clinician or go to the hospital)

**Reviewed regularly:** The written personalized asthma action plan should be reviewed at every asthma-related health care encounter, after a severe exacerbation of symptoms, when there is a change in the person's level of asthma control or a change in treatment, or at least annually.

**Clinician:** Many types of clinicians may be involved in providing and reviewing asthma action plans and providing self-management education. Asthma action plans can be provided by primary care clinicians, such as family doctors or nurse practitioners, or by respirologists, allergists, and other clinicians. In addition, nurses, respiratory therapists, pharmacists, and other clinicians who are CREs or CAEs can review asthma action plans and provide self-management education.

## Rationale

Providing self-management education on inhaler technique, along with written personalized asthma action plans that reinforce understanding of medication and are regularly reviewed by a clinician, can significantly improve people's asthma management and their health outcomes.<sup>4,44,45</sup> In practice currently, self-management education remains poorly implemented and patients rarely receive written asthma action plans. For example, in a 2004 survey, only 22% of Canadian physicians reported consistently providing written asthma action plans, while 11% of patients reported receiving one.<sup>22</sup> Chart audits of primary and emergency department care in Ontario and Alberta have shown that the overwhelming majority of patients with asthma do not have asthma action plans.<sup>15,44,46</sup>

## What This Quality Statement Means

### For Adults With Asthma

Your clinician should explain asthma to you, including what you can do to take care of yourself. You, your care partners (if you want them involved), and your clinician should work together to write your personal asthma action plan. This plan describes:

- Your medications and how to take them
- Things you can do each day to stay healthy
- What to do if your symptoms flare up

### For Clinicians

When prescribing medication, provide asthma self-management education to adults with asthma and their care partners, and work with them to create a written personalized asthma action plan that considers literacy, usability, and language. Ensure they receive information about and referrals to local service providers who can help them learn how to avoid or reduce exposure to triggers and improve their ability to self-manage (e.g., referral to asthma education, team-based care, or social services).

When dispensing medication, ensure it aligns with the person's asthma action plan and review the plan with them.

### For Organizations and Health Services Planners

Ensure training, systems, processes, and resources are in place in primary care and community-based settings for clinicians to provide and review asthma action plans and self-management education with adults with asthma and their care partners. Ensure adults with asthma and their care partners have access to clinicians trained in providing asthma self-management education and asthma action plans, including, but not limited to, respiratory therapists and other clinicians who are CREs or CAEs.

## Quality Indicators: How to Measure Improvement for This Statement

- Percentage of adults with asthma who have ever received asthma self-management education from a trained clinician
- Percentage of adults with asthma who have received a written personalized asthma action plan
- Percentage of adults with asthma who have a written personalized asthma action plan and who have had their asthma action plan reviewed in the previous 12 months

Measurement details for these indicators, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).

# Quality Statement 5: Referral to Specialized Asthma Care

Adults who meet criteria for severe asthma or have other appropriate indications are referred to specialized asthma care.

Sources: British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network, 2024<sup>8</sup> | Canadian Thoracic Society, 2021a<sup>4</sup> | European Respiratory Society, 2022<sup>31</sup> | Registered Nurses' Association of Ontario, 2017<sup>11</sup>

## Definitions

**Severe asthma:** “Asthma which requires treatment with high-dose ICS [as outlined in the current CTS guideline<sup>4</sup>] and a second controller for the previous year, or systemic corticosteroids for 50% of the previous year to prevent it from becoming ‘uncontrolled,’ or which remains ‘uncontrolled’ despite this therapy.”<sup>4</sup> Before categorizing a person’s asthma as severe, clinicians should assess asthma control using a structured assessment and thoroughly assess reasons for poor control (see quality statement 2). Further investigations and certain treatments for severe asthma may be better suited to care by asthma specialists.

**Appropriate indications:** Appropriate indications for referral to specialized asthma care include, but are not limited to, the following categories:

- The person’s inability to complete lung function testing
- Diagnostic uncertainty (e.g., having obstructive spirometry but negative bronchodilator reversibility, symptoms suggestive of asthma but negative spirometry and negative peak flow variability)
- Near-fatal exacerbations
- Uncontrolled asthma in pregnancy
- Severe asthma
- Confirmed or suspected work-related asthma (i.e., occupational or work-aggravated asthma)
- Suspected side effects of treatment (e.g., fungal or yeast infections, osteoporosis)
- Any asthma-related hospitalization or  $\geq 2$  exacerbations requiring care in the emergency department<sup>4</sup>
- Need for allergy testing to assess the possible role of environmental allergens

**Specialized asthma care:** Depending on the clinical indication, 1 or more of the following professionals may provide specialized asthma care:

- A respirologist
- An allergist
- A general internist with expertise in respiratory medicine
- A clinician with expertise in asthma and/or working within a specialized asthma clinic, such as a family physician, a nurse practitioner, a nurse, a respiratory therapist, or another clinician who is a CRE or CAE

## Rationale

Most adults with asthma can effectively manage their disease and symptoms with appropriate medication, self-management education, and support from primary care. However, some people continue to have uncontrolled asthma despite appropriate asthma medication (see quality statement 3) or require maximal doses of medication to achieve control, and they may have severe asthma.<sup>4,10</sup> In such clinical situations, a referral to specialized asthma care may be needed for expert advice about diagnosis and/or management.<sup>4,10</sup> To promote patient-centred care, the referral process should involve an integrated approach in which there is collaboration, communication, and shared decision-making among clinicians and the person with asthma.

A recent chart audit of a convenience sample of primary care clinics in Ontario highlighted that wait times (the duration between a patient's referral and their specialist visit) vary across clinical specialties (median of 79 days for nonurgent referrals and 49 days for urgent referrals).<sup>47</sup> Electronic tools for specialist consultation such as eConsult or virtual visits can be used to improve wait times for specialized asthma care.

## What This Quality Statement Means

### For Adults With Asthma

If you take your medication and avoid triggers as much as possible but continue to have asthma symptoms, or if your primary care clinician has other concerns, they should consult with or refer you to specialized asthma care.

### For Clinicians

Ensure adults with severe asthma or other appropriate indications (see definitions in this statement) are referred to specialized asthma care. After seeing the patient, the specialized asthma care clinician should communicate the recommended plan for treatment and follow-up (if needed) to the primary care clinician. In some cases, a consultation between the primary care clinician and specialized asthma care clinician may be required or sufficient; that is, the patient may not need to visit the specialized clinician.

All clinicians involved should ensure the entire referral process involves collaboration, communication, and shared decision-making among clinicians, the person with asthma, and their care partners.

## For Organizations and Health Services Planners

Ensure systems, processes, and resources are in place so all adults with asthma have timely access to specialized asthma care when needed upon referral from their primary care clinician, including the use of eReferral, eConsult, and virtual visits. Ensure clinicians in primary care and community-based care are aware of the asthma services and referral processes in their communities.<sup>11</sup>

# Quality Indicators: How to Measure Improvement for This Statement

- Percentage of adults with severe asthma or 1 or more appropriate indications who are referred to specialized asthma care
- Percentage of adults with asthma who have 2 or more asthma-specific emergency department visits or 1 or more asthma-specific hospitalizations and who then have a consultation with a relevant specialist clinician within 3 months of the index event

Measurement details for these indicators, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).

# Quality Statement 6: Follow-Up After Discharge

Adults who have had an emergency department visit or been hospitalized for an asthma exacerbation have a follow-up assessment within 2 to 7 days after discharge.

Source: Advisory committee consensus

## Definitions

**Asthma exacerbation:** This can occur in people with a pre-existing diagnosis of asthma (even when mild or well controlled) or, occasionally, as the first presentation of asthma. It is an episode characterized by a progressive worsening in symptoms of shortness of breath, cough, wheezing, or chest tightness, and a progressive decrease in lung function. Asthma exacerbations represent a big enough change from the person's usual status to require a change in treatment (e.g., the use of oral corticosteroids), an emergency department visit, or hospitalization. Exacerbations often occur in response to irritant or allergic trigger exposures (e.g., viral, bacterial, or fungal infection in the upper or lower respiratory tract, air pollution, smoke, pollen) and/or inadequate controller medication adherence. However, a subset of people present with exacerbations without trigger exposures.

**Follow-up assessment:** Adults should be assessed in primary care or an asthma clinic within 2 to 7 days of an emergency department visit or hospital discharge and reassessed regularly over subsequent weeks until they achieve asthma control and reach or surpass their personal best lung function (see quality statement 2). The initial follow-up may be completed by primary care clinicians, such as family doctors or nurse practitioners, or by respirologists, allergists, and other physicians or other members of the care team, such as nurses, respiratory therapists, and pharmacists who are CREs or CAEs. In some cases, a phone or virtual follow-up may be sufficient.<sup>10</sup>

The follow-up assessment should be individualized and related to the details of the emergency department visit or hospitalization. Components of the follow-up assessment include, but are not limited to, a review of the following:

- The person's or their care partners' understanding of the cause of the asthma exacerbation
- Asthma control, reasons for poor control, and risk of future exacerbations (see quality statement 2)
- Changes in medication as needed by prescribing primary care clinicians, including discontinuation of oral corticosteroids (see quality statement 3)
- Asthma action plan (see quality statement 4)

- Self-management education, including medication adherence, inhaler technique, and avoidance or reduction of trigger exposures (see quality statement 4)

The follow-up assessment should also include a referral to an asthma education program, and adults who were hospitalized (particularly if they required treatment in an intensive care unit) should be referred to specialized asthma care (see quality statement 5).<sup>10</sup>

## Rationale

Asthma exacerbations can be life-threatening emergencies and may require care in an emergency department or a hospitalization.<sup>10</sup> The subsequent transition from hospital to home can complicate a person's care, as transitions are vulnerable points in the provision of health care.<sup>48</sup> Transitions pose a risk of information being lost or miscommunicated between health care settings, which can increase the person's vulnerability to adverse events.<sup>49</sup>

The need for acute care in adults with asthma should be considered a failure of asthma management, and their transition back to primary care should provide an opportunity to address gaps in care and/or self-management.<sup>4</sup> Gaps in the quality of hospital-based care may also increase vulnerability to adverse events. For example, the Ontario Asthma Regional Variation Study documented important care gaps in Ontario emergency departments, including underutilization of systemic steroids on discharge (in about 33% of adult patients) and failure to refer patients to specialized asthma care (about 2.7%).<sup>50</sup>

Prompt follow-up in primary care or referral to an asthma clinic can mitigate these risks. In some patients with respiratory or chronic illnesses other than asthma, early follow-up has been linked to improved patient outcomes and reduced rates of readmission, emergency department use, and death.<sup>49</sup>

For more information on discharge planning and follow-up in primary care after discharge, please see the quality standard [Transitions Between Hospital and Home](#).<sup>51</sup>

## What This Quality Statement Means

### For Adults With Asthma

If you went to the emergency department or were hospitalized because of an asthma flare-up, your primary care clinician should follow up with you within 2 to 7 days to see how you are doing and make any needed changes to your medications or your asthma action plan. In some cases, the initial follow-up may be done by a respirologist, allergist, or another clinician, or by other members of the care team such as nurses, respiratory therapists, and pharmacists who are CREs or CAEs. At this visit, you can also ask questions to make sure you understand:

- What caused the flare-up
- What care you received
- What you can do to prevent asthma flare-ups



## For Clinicians

Before an adult who has had an asthma exacerbation is discharged from an emergency department, the care team should tell the person with asthma to arrange a follow-up primary care appointment. If the person was hospitalized, the hospital care team should arrange for a follow-up assessment in primary care. In either setting, the care team should send the person's discharge information directly to their primary care clinician. Primary care follow-up is important to ensure the person's treatment continues, their asthma symptoms are well controlled, and their lung function reaches their known personal best.

Following discharge, consider referral to an asthma education program or specialized asthma care.<sup>10</sup>

## For Organizations and Health Services Planners

Ensure systems, processes, and resources are in place so all adults have timely access to follow-up in primary care after an asthma-specific emergency department visit or hospitalization. This includes ensuring all adults with asthma have a primary care clinician, arrangements for a follow-up assessment in primary care are made, and seamless communication is possible between hospital and primary care settings.

# Quality Indicator: How to Measure Improvement for This Statement

- Percentage of adults who have a follow-up assessment in primary care or an asthma clinic within 7 days following an emergency department visit or hospitalization for an asthma exacerbation

Measurement details for this indicator, as well as overarching indicators to measure improvement for the goals of the entire quality standard, are available in the [technical specifications](#).



# Appendix 1: About This Quality Standard

## How to Use This Quality Standard

Quality standards inform patients, clinicians, and organizations about what high-quality care looks like for health conditions or processes deemed a priority for quality improvement in Ontario. They are based on the best evidence.

Guidance on how to use quality standards and their associated resources is included below.

### For Adults With Asthma

This quality standard consists of quality statements. These describe what high-quality care looks like for adults with asthma.

Within each quality statement, we have included information on what these statements mean for you as an adult with asthma.

In addition, you may want to download this accompanying [patient guide](#) on asthma to help you and your family have informed conversations with your clinicians. Inside, you will find information and questions you may want to ask as you work together to make a plan for your care.

### For Clinicians and Organizations

The quality statements within this quality standard describe what high-quality care looks like for adults with asthma. They are based on the best evidence and designed to help you know what to do to reduce gaps and variations in care.

Many clinicians and organizations are already providing high-quality, evidence-based care. However, there may be elements of your care that can be improved. This quality standard can serve as a resource to help you prioritize and measure improvement efforts.

Tools and resources to support you in your quality improvement efforts accompany each quality standard. These resources include indicators and their definitions, available in the technical specifications. Measurement is key to quality improvement. Collecting and using data when implementing a quality standard can help you assess the quality of care you are delivering and identify gaps in care and areas for improvement.

There are also a number of resources online to help you, including:

- Our [patient guide](#) on asthma, which you can share with patients and families to help them have conversations with you and their other clinicians. Please make the patient guide available where you provide care
- Our [measurement resources](#), including the technical specifications for the indicators in this quality standard, the “case for improvement” slide deck to help you to share why this standard

was created and the data behind it, and our measurement guide containing supplementary information to support the data collection and measurement processes

- Our [placemat](#), which summarizes the quality standard and includes links to helpful resources and tools
- Our [Getting Started Guide](#), which includes links to templates and tools to help you put quality standards into practice. This guide shows you how to plan for, implement, and sustain changes in your practice
- [Quorum](#), an online community dedicated to improving the quality of care across Ontario. This is a place where clinicians can share information and support each other, and it includes tools and resources to help you implement the quality statements within each standard

## How the Health Care System Can Support Implementation

As you work to implement this quality standard, there may be times when you find it challenging to provide the care outlined due to system-level barriers or gaps. These challenges have been identified and documented as part of the development of the quality standard, which included extensive consultation with clinicians and lived experience advisors and a careful review of available evidence and existing programs. Many of the levers for system change fall within the purview of Ontario Health, and as such we will continue to work to address these barriers to support the implementation of quality standards. We will also engage and support other provincial partners, including the Ministry of Health or other relevant ministries, on policy-level initiatives to help bridge system-level gaps.

In the meantime, there are many actions you can take on your own, so please read the standard and act where you can.

# Appendix 2: Glossary

Term	Definition
<b>Adults</b>	People aged 16 years and older.
<b>Care partner</b>	An unpaid person who provides care and support in a nonprofessional capacity, such as a parent, other family member, friend, or anyone else identified by the person with asthma. Other terms commonly used to describe this role include “caregiver,” “informal caregiver,” “family caregiver,” “carer,” and “primary caregiver.”
<b>Clinicians</b>	Regulated professionals who provide care to patients or clients. Examples are nurses, nurse practitioners, occupational therapists, respiratory therapists, pharmacists, physicians, physiotherapists, psychologists, social workers, and speech-language pathologists.
<b>Controller medication</b>	An inhaler or puffer that prevents asthma symptoms by reducing the swelling of the airways in the lungs.
<b>Family</b>	The people closest to a person in terms of knowledge, care, and affection; this may include biological family or family of origin, family through marriage, or family of choice and friends. The person defines their family and who will be involved in their care.
<b>Home</b>	A person’s usual place of residence. This may include personal residences, retirement residences, assisted-living facilities, long-term care facilities, hospices, and shelters.
<b>Prescriber</b>	A physician, nurse practitioner, or dentist who is authorized to prescribe medication.
<b>Primary care</b>	A setting where people receive general health care (e.g., screening, diagnosis, and management) from a clinician who the person can access directly without a referral. This is usually the primary care clinician, family physician, nurse practitioner, or other clinician with the ability to make referrals, request laboratory testing, and prescribe medications.
<b>Primary care clinician</b>	A family physician (also called a primary care physician) or nurse practitioner.
<b>Rescue or reliever medication</b>	An inhaler or puffer that relieves asthma symptoms quickly by opening the airways.
<b>Transitions in care</b>	These occur when patients transfer between different care settings (e.g., hospital, primary care, long-term care, home and community care) or between different clinicians during the course of an acute or chronic illness.

# Appendix 3: Values and Guiding Principles

## Values That Are the Foundation of This Quality Standard

This quality standard was created, and should be implemented, according to the [Patient, Family and Caregiver Declaration of Values for Ontario](#). This declaration “is a vision that articulates a path toward patient partnership across the health care system in Ontario. It describes a set of foundational principles that are considered from the perspective of Ontario patients, and serves as a guidance document for those involved in our health care system.”

These values are:

- Respect and dignity
- Empathy and compassion
- Accountability
- Transparency
- Equity and engagement

A quality health system is one that provides good access, experience, and outcomes for all people in Ontario, no matter where they live, what they have, or who they are.

## Guiding Principles

In addition to the above values, this quality standard is guided by the principles outlined below.

### Acknowledging the Impact of Colonization

Clinicians should acknowledge and work toward addressing the historical and present-day impacts of colonization in the context of the lives of Indigenous Peoples and racialized people throughout Canada. This work involves being sensitive to the impacts of intergenerational and present-day traumas and the physical, mental, emotional, and social harms experienced by Indigenous and racialized people, families, and communities, as well as recognizing their strength and resilience. This quality standard uses existing clinical practice guideline sources that may not include culturally appropriate care or acknowledge traditional beliefs, practices, and models of care relevant to Indigenous and racialized people.

### French Language Services

In Ontario, the *French Language Services Act* guarantees an individual’s right to receive services in French from Government of Ontario ministries and agencies in [27 designated areas](#) and at government head offices.<sup>52</sup>

## Social Determinants of Health

Homelessness and poverty are 2 examples of economic and social conditions that influence people's health, known as the social determinants of health. Other social determinants of health include employment status and working conditions, race and ethnicity, food security and nutrition, gender, housing, immigration status, social exclusion, and residing in a rural or urban area. Social determinants of health can have strong effects on individual and population health; they play an important role in understanding the root causes of poorer health. Adults with asthma should be provided services that are respectful of their gender, sexual orientation, socioeconomic status, housing, age, background (including self-identified cultural, ethnic, and religious background), and disability. Equitable access to the health system also includes access to culturally safe care. Language, a basic tool for communication, is an essential part of safe care and must be considered throughout a person's health care journey. For example, in predominantly English-speaking settings, services should be actively offered in French and other languages.

## Chronic Disease Self-Management

Adults with asthma should receive services that are respectful of their rights and dignity and that promote shared decision-making and self-management.<sup>53,54</sup> Further, people should be empowered to make informed choices about the services that best meet their needs.<sup>55,56</sup> Adults with asthma should engage with their clinicians in informed, shared decision-making about their treatment options. Each person is unique and has the right to determine their own path toward health and well-being.<sup>53</sup>

## Integrated Care

Adults with asthma should receive care through an integrated team-based approach that facilitates access to interprofessional services from primary care clinicians, specialized asthma care, and programs in the community, according to the patient's needs over time.<sup>57</sup> Clinicians should work with patients, their families and care partners, and communities to deliver the highest quality of care.<sup>58</sup> Interprofessional collaboration, shared decision-making, coordination of care across different settings within and beyond the health sector, and continuity of care (including follow-up care) are hallmarks of this patient-centred approach.<sup>57</sup>

## Trauma-Informed Care

Trauma-informed care is health care that reflects an understanding of trauma, the impact that traumatic experiences can have on human beings, and the potential to traumatize or retraumatize patients when providing them with care.<sup>59,60</sup> A trauma-informed approach does not necessarily involve addressing the trauma directly. Rather, it involves acknowledging that a person may have experienced a previous traumatic event that may contribute to their current health concerns, and taking steps to reduce opportunities for traumatization (e.g., using active strategies around consent, attending to individual patient needs, recognizing the inherent power imbalance in clinician-patient relationships, and facilitating greater patient agency and choice in all interactions).<sup>61,62</sup> A trauma-informed approach emphasizes the creation of an environment in which a person can feel comfortable disclosing trauma, and it involves understanding, respecting, and responding to the effects of trauma.<sup>60-62</sup>

# Acknowledgements

## Advisory Committee

Ontario Health thanks the following individuals for their generous, voluntary contributions of time and expertise to help create this quality standard (credentials at the time of initial development in 2020):

### **Samir Gupta (co-chair)**

Adult Respiriologist, St. Michael's Hospital;  
Assistant Professor, University of Toronto;  
Adjunct Scientist, Keenan Research Centre,  
Li Ka Shing Knowledge Institute, St. Michael's  
Hospital

### **Dhenuka Radhakrishnan (co-chair)**

Pediatric Respiriologist and Clinical Investigator,  
Children's Hospital of Eastern Ontario;  
Assistant Professor, Department of Pediatrics,  
University of Ottawa; Adjunct Scientist, ICES

### **Janice Belanger**

Certified Respiratory Educator, Group Health  
Centre

### **Madonna Ferrone**

Coordinator, Project Manager, Certified  
Respiratory Educator, Asthma Research  
Group Inc. and Hôtel Dieu Grace Hospital

### **Andrea S. Gershon**

Senior Scientist, Sunnybrook Research Institute  
and ICES; Associate Professor, University of  
Toronto; Respiriologist, Sunnybrook Health  
Sciences Centre

### **Carmela Graziani (2018–2020)**

Lived Experience Advisor

### **Samim Hasham**

Clinical Pharmacist; Faculty, Adler College  
Toronto

### **Julie Hunter**

Nurse Practitioner, Lady Dunn Health Centre

### **Alan Kaplan**

Family Physician; Chair, Family Physician  
Airways Group of Canada; Clinical Lecturer,  
University of Toronto

### **Diane Lougheed**

Professor of Medicine, Public Health Sciences,  
and Biomedical and Molecular Sciences, Chair  
of Division of Respiriology, Queen's University;  
Senior Adjunct Scientist, ICES

### **Kate Mulligan**

Lived Experience Advisor; Director, Policy and  
Communications, Alliance for Healthier  
Communities

### **Zoe Nugent**

Staff Physician/Pediatric Respiriologist,  
Peterborough Regional Health Centre,  
The Peterborough Clinic

### **Delanya Podgers**

Nurse Practitioner – Asthma and COPD,  
Kingston Health Sciences Centre

### **Jessica Schooley**

Primary Care Asthma Program Site Coordinator  
and Certified Respiratory Educator, Pediatric  
Asthma Clinic, Kingston Health Sciences Centre

### **Ryan Smith**

Staff Paediatrician, Medical Director,  
Paediatric Asthma Clinic, Orillia Soldiers'  
Memorial Hospital

**Christina Sperling**

Director, Respiratory Health Program, Lung Health Foundation

**Itamar Tamari**

Family Physician, Stonegate Community Health Centre; Medical Director, Primary Care Asthma Program

**Teresa To**

Professor, Dalla Lana School of Public Health, University of Toronto; Senior Scientist, The Hospital for Sick Children; Director, Ontario Asthma Surveillance Information System

**Christine Truong**

Clinical Pharmacist; Certified Respiratory Educator, North York Family Health Team

**Angelina Wiwczor**

Nurse Practitioner, Certified Asthma Educator, Health Sciences North – NEO Kids, Kids Care Centre

**Calvin Young**

Lived Experience Advisor



# References

- (1) Ontario Health. Asthma in children and adolescents: care in the community for people under 16 years of age [Internet]. Toronto (ON): King's Printer for Ontario; 2025 [cited 2025 Mar 7]. Available from: <https://hqontario.ca/evidence-to-improve-care/quality-standards/view-all-quality-standards/asthma-in-children-and-adolescents>
- (2) Bhakta NR, Bime C, Kaminsky DA, McCormack MC, Thakur N, Stanojevic S, et al. Race and ethnicity in pulmonary function test interpretation: an official American Thoracic Society statement. *Am J Respir Crit Care Med*. 2023;207(8):978-95.
- (3) Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J*. 2022;60(1):2101499.
- (4) Yang CL, Hicks EA, Mitchell P, Reisman J, Podgers D, Hayward KM, et al. Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. *Can J Respir Crit Care Sleep Med*. 2021a;5(6):348-61.
- (5) Yang CL, Hicks EA, Mitchell P, Reisman J, Podgers D, Hayward KM, et al. 2021 Canadian Thoracic Society guideline – a focused update on the management of very mild and mild asthma. *Can J Respir Crit Care Sleep Med*. 2021b;5(4):205-45.
- (6) Choosing Wisely Canada, and Canadian Thoracic Society. Recommendations: respiratory medicine [Internet]. 2023 [cited 2025 Mar 7]. Available from: <https://choosingwiselycanada.org/recommendation/respiratory-medicine/>
- (7) Gupta S, Couillard S, Digby G, Tse SM, Green S, Acheron R, et al. Canadian Thoracic Society position statement on climate change and choice of inhalers for patients with respiratory disease. *Can J Respir Crit Care Sleep Med*. 2023;7(5):232-9.
- (8) British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN). Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) 2024 [cited 2025 Mar 7]. Available from: <https://www.nice.org.uk/guidance/NG245>
- (9) National Institute for Health and Care Excellence. Asthma. Quality standard [Internet]. London (UK): The Institute; 2013 (2018 update) [cited 2019 Mar]. Available from: <https://www.nice.org.uk/guidance/qs25/>
- (10) Global Initiative for Asthma. Global strategy for asthma management and prevention [Internet]. Fontana (WI): The Initiative; 2024 [cited 2025 Mar 5]. Available from: <https://ginasthma.org/reports/>
- (11) Registered Nurses' Association of Ontario. Adult asthma care: promoting control of asthma [Internet]. Toronto (ON): The Association; 2017 May [cited 2019 Jan 21]. Available from: [https://rnao.ca/sites/rnao-ca/files/bpg/Adult\\_Asthma\\_FINAL\\_WEB.pdf](https://rnao.ca/sites/rnao-ca/files/bpg/Adult_Asthma_FINAL_WEB.pdf)
- (12) Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. *J Allergy Clin Immunol*. 2009;123(3):519-28; quiz 29-30.
- (13) Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. *J Allergy Clin Immunol*. 2009;123(3):531-42; quiz 43-4.
- (14) Ontario Asthma Surveillance & Information System, ICES. Asthma prevalence crude rates (per 100 Ontario population) [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids);



- 2024 [cited 2025 Feb 5]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma\\_prevrt\\_2022.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma_prevrt_2022.pdf)
- (15) Ontario Asthma Surveillance & Information System, ICES. Asthma incidence crude rates (per 1,000 Ontario population) [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids); 2024 [cited 2025 Feb 5]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma\\_incrtr\\_2022-2.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma_incrtr_2022-2.pdf)
  - (16) Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract*. 2017;3:1.
  - (17) Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. *BMC Pulm Med*. 2013;13:70.
  - (18) Gaffin JM, Castro M, Bacharier LB, Fuhlbrigge AL. The role of comorbidities in difficult-to-control asthma in adults and children. *J Allergy Clin Immunol Pract*. 2022;10(2):397-408.
  - (19) Loughheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Management Continuum: 2010 consensus summary for children six years of age and over, and adults. *Can Respir J*. 2010;17(1):15-24.
  - (20) Loughheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. *Can Respir J*. 2012 Mar/Apr;19(2):127-64.
  - (21) FitzGerald JM, Lemiere C, Loughheed MD, Ducharme FM, Dell SD, Ramsey C, et al. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. *Can J Respir Crit Care Sleep Med* [Internet]. 2017 [cited 2019 Apr 29]; 1(4):[23 p.]. Available from: <https://doi.org/10.1080/24745332.2017.1395250>
  - (22) FitzGerald JM, Boulet LP, McIvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. *Can Respir J*. 2006;13:253-9.
  - (23) The Lung Association. Moving the dial on the diagnosis and treatment of asthma [Internet]. Toronto (ON): The Association; 2019 Jan [cited 2019 May 13]. Available from: [https://www.lung.ca/sites/default/files/MovingtheDial\\_WhitePaper.pdf](https://www.lung.ca/sites/default/files/MovingtheDial_WhitePaper.pdf)
  - (24) Ontario Asthma Surveillance & Information System, ICES. Asthma, Asthma-related, and All-cause Mortality, from 2000 to 2018 [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids); 2021 [cited 2025 Mar 7]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2021/06/mortality\\_onpop\\_2000-2018\\_v2.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2021/06/mortality_onpop_2000-2018_v2.pdf)
  - (25) To T, Simatovic J, Zhu J, Feldman L, Dell SD, Loughheed MD, et al. Asthma deaths in a large provincial health system. A 10-year population-based study. *Ann Am Thorac Soc*. 2014;11(8):1210-7.
  - (26) Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, et al. Direct health care costs associated with asthma in British Columbia. *Can Respir J* [Internet]. 2010 [cited 2019 Apr 29]; 17(2):[7 p.]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866215/>
  - (27) Ontario Asthma Surveillance & Information System, ICES. Asthma-related emergency department visits [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids); 2024 [cited 2025 Feb 5]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma\\_rel\\_ed\\_2022.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma_rel_ed_2022.pdf)
  - (28) Ontario Asthma Surveillance & Information System, ICES. Asthma-related hospitalizations [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids); 2024 [cited 2025 Feb 5]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma\\_rel\\_cihi\\_2022.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/asthma_rel_cihi_2022.pdf)

- (29) Smetanin P, Stiff D, Briante C, Ahmad S, Wong L, Ler A. Life and economic impact of lung disease in Ontario: 2011 to 2041 [Internet]. Toronto (ON): RiskAnalytica on behalf of the Ontario Lung Association; 2011 [cited 2019 Apr 29]. Available from: <http://lungontario.ca/wp-content/uploads/2017/09/OLA-Final-Report-June-281.pdf>
- (30) Stonebridge C, Goldfarb D, Bounajm F, Hermus G T, Heriault L. Cost risk analysis for chronic lung disease in Canada [Internet]. Ottawa (ON): Conference Board of Canada; 2012 [cited 2025 Mar 7]. Available from: <https://www.conferenceboard.ca/product/cost-risk-analysis-for-chronic-lung-disease-in-canada/>
- (31) Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. *Eur Respir J*. 2022;2101585.
- (32) National Heart, Lung, and Blood Institute, and National Institutes of Health. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group 2020 [cited 2025 Mar 7]. Available from: <https://www.nhlbi.nih.gov/resources/2020-focused-updates-asthma-management-guidelines>
- (33) Ontario Health. Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment. *Ont Health Technol Assess Ser* [Internet]. 2024; Jul; 1-24(5):[1-225 pp.]. Available from: <https://www.hqontario.ca/Evidence-to-Improve-Care/Health-Technology-Assessment/Reviews-And-Recommendations/Fractional-Exhaled-Nitric-Oxide-Testing-for-the-Diagnosis-and-Management-of-Asthma>
- (34) Kitazawa H, Jiang A, Nohra C, Ota H, Wu JKY, Ryan CM, et al. Changes in interpretation of spirometry by implementing the GLI 2012 reference equations: impact on patients tested in a hospital-based PFT lab in a large metropolitan city. *BMJ Open Respir Res*. 2022;9(1).
- (35) Bowerman C, Bhakta NR, Brazzale D, Cooper BR, Cooper J, Gochicoa-Rangel L, et al. A race-neutral approach to the interpretation of lung function measurements. *Am J Respir Crit Care Med*. 2023;207(6):768-74.
- (36) Marciniuk DD, Becker EA, Kaminsky DA, McCormack MC, Stanojevic S, Bhakta NR, et al. Effect of race and ethnicity on pulmonary function testing interpretation: an American College of Chest Physicians (CHEST), American Association for Respiratory Care (AARC), American Thoracic Society (ATS), and Canadian Thoracic Society (CTS) evidence review and research statement. *Chest*. 2023;164(2):461-75.
- (37) Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med*. 2019;200(8):e70-e88.
- (38) Coates AL, Wanger J, Cockcroft DW, Culver BH, Diamant Z, Gauvreau G, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. *Eur Respir J*. 2017;49(5).
- (39) Ontario Asthma Surveillance Information System, ICES. Asthma indicators for all of Ontario, 1996-2022 [Internet]. Toronto (ON): The Hospital for Sick Children (SickKids); 2022 [cited 2025 Mar 5]. Available from: [https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/ast\\_indicators\\_Ontario\\_2022.pdf](https://lab.research.sickkids.ca/oasis/wp-content/uploads/sites/6/2024/07/ast_indicators_Ontario_2022.pdf)
- (40) Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemiere C, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. *JAMA*. 2017;317(3):269-79.
- (41) Global Initiative for Asthma. Global strategy for asthma management and prevention (2019 update) [Internet]. Fontana (WI): The Initiative; 2019 [cited 2019 Nov]. Available from:

<https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf>

- (42) Price C, Agarwal G, Chan D, Goel S, Kaplan AG, Boulet LP, et al. Large care gaps in primary care management of asthma: a longitudinal practice audit. *BMJ Open*. 2019 9(e022506):1-10.
- (43) Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. *Lancet*. 2017;389(10065):157-66.
- (44) FitzGerald JM, Boulet L-P, McIvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. *Can Respir J*. 2006;13(5):253-9.
- (45) Burgess S, Sly P, Devadason S. Adherence with preventive medication in childhood asthma. *Pulm Med*. 2011;2011:973849.
- (46) Tsuyuki RT, Sin DD, Sharpe HM, Cowie RL, Nilsson C, Man SF. Management of asthma among community-based primary care physicians. *J Asthma*. 2005;42(3):163-7.
- (47) Liddy C, Nawar N, Moroz I, McRae S, Russell C, Mihan A, et al. Understanding patient referral wait times for specialty care in Ontario: a retrospective chart audit. *Healthcare Policy*. 2018;13(3):59-69.
- (48) Naylor M, Keating SA. Transitional care: moving patients from one care setting to another. *Am J Nurs*. 2008;108 Suppl 9:58-63.
- (49) Health Quality Ontario. Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review. *Ont Health Technol Assess Ser* [Internet]. 2017 May;17(8):1-37. Available from: <http://www.hqontario.ca/Evidence-to-Improve-Care/Journal-Ontario-Health-Technology-Assessment-Series>.
- (50) Loughheed MD, Garvey N, Chapman KR, Cicutto L, Dales R, Day AG, et al. The Ontario Asthma Regional Variation Study: emergency department visit rates and the relation to hospitalization rates. *Chest*. 2006;129(4):909-17.
- (51) Ontario Health. Transitions between hospital and home: care for people of all ages [Internet]. Toronto (ON): Queen's Printer for Ontario; 2020 [cited 2025 Mar 7]. Available from: <https://hqontario.ca/evidence-to-improve-care/quality-standards/view-all-quality-standards/transitions-between-hospital-and-home>
- (52) Ministry of Health and Ministry of Long-Term Care. French language health services: *the French Language Services Act*, 1986 (FLSA) [Internet]. Toronto (ON): Queen's Printer for Ontario; 2021 [cited 2025 Mar 5]. Available from: <https://www.health.gov.on.ca/en/public/programs/flhs/flsa.aspx>
- (53) Mack DP, Greenhawt M, Bukstein DA, Golden DBK, Settipane RA, Davis RS. Decisions with patients, not for patients: shared decision-making in allergy and immunology. *J Allergy Clin Immunol Pract*. 2024;12(10):2625-33.
- (54) The Electronic Asthma Management System (eAMS). Mild asthma decision aid and conversation aid [Internet]. 2025 [cited 2025 Mar 26]. Available from: <https://www.asthmadecisionaid.com/>
- (55) Clayman ML, Scheibler F, Rüffer JU, Wehkamp K, Geiger F. The Six Steps of SDM: linking theory to practice, measurement and implementation. *BMJ Evid Based Med*. 2024;29(2):75-8.
- (56) National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence [Internet]. London (UK): The Institute; 2009 [cited 2025 Mar 5]. Available from: <https://www.nice.org.uk/guidance/cg76>

- (57) World Health Assembly. Framework on integrated, people-centred health services: report by the Secretariat [Internet]. Geneva: World Health Organization; 2016 [cited 2025 Mar 05]. Available from: <https://iris.who.int/handle/10665/252698>
- (58) Khalili H, Gilbert J, Lising D, MacMillan K.M, Xyrichis A. Proposed lexicon for the interprofessional field [Internet]: Interprofessional Research Global; 2021 [cited 2025 Mar 6]. Available from: <https://interprofessionalresearch.global/wp-content/uploads/2021/10/InterprofessionalResearch.Global-IPECP-Lexicon-2021-Reprint.pdf>
- (59) Kuehn BM. Trauma-informed care may ease patient fear, clinician burnout. JAMA. 2020;323(7):595-7.
- (60) Ravi A, Little V. Providing trauma-informed care. Am Fam Physician. 2017;95(10):655-7.
- (61) Dowdell EB, Speck PM. CE: trauma-informed care in nursing practice. Am J Nurs. 2022;122(4):30-8.
- (62) Fleishman J, Kamsky H, S. S. Trauma-informed nursing practice. Online J Issues Nurs. 2019;24(2).

# About Us



We are an agency created by the Government of Ontario to connect, coordinate, and modernize our province's health care system. We work with partners, providers, and patients to make the health system more efficient so everyone in Ontario has an opportunity for better health and well-being.

## Equity, Inclusion, Diversity, and Anti-Racism

Ontario Health is committed to advancing equity, inclusion and diversity and addressing racism in the health care system. As part of this work, Ontario Health has developed an [\*Equity, Inclusion, Diversity and Anti-Racism Framework\*](#), which builds on existing legislated commitments and relationships and recognizes the need for an intersectional approach.

Unlike the notion of equality, equity is not about sameness of treatment. It denotes fairness and justice in process and in results. Equitable outcomes often require differential treatment and resource redistribution to achieve a level playing field among all individuals and communities. This requires recognizing and addressing barriers to opportunities for all to thrive in our society.

For more information about Ontario Health, visit [OntarioHealth.ca](https://ontariohealth.ca).

# Looking for More Information?

Visit [hqontario.ca](https://hqontario.ca) or contact us at [QualityStandards@OntarioHealth.ca](mailto:QualityStandards@OntarioHealth.ca) if you have any questions or feedback about this quality standard.

**Ontario Health**  
500–525 University Avenue  
Toronto, Ontario  
M5G 2L3

**Toll Free:** 1-877-280-8538  
**TTY:** 1-800-855-0511  
**Email:** [QualityStandards@OntarioHealth.ca](mailto:QualityStandards@OntarioHealth.ca)  
**Website:** [hqontario.ca](https://hqontario.ca)

Need this information in an accessible format? 1-877-280-8538, TTY 1-800-855-0511, [info@OntarioHealth.ca](mailto:info@OntarioHealth.ca)

Document disponible en français en contactant [info@OntarioHealth.ca](mailto:info@OntarioHealth.ca)

ISBN 978-1-4868-8858-0 (PDF)  
© King's Printer for Ontario, 2025